Total Payments
$78,512
2024 Payments
$17,391
Companies
81
Transactions
859
Medicare Patients
10,472
Medicare Billing
$2.6M
Payment Breakdown by Category
Consulting$37,851 (48.2%)
Food & Beverage$18,046 (23.0%)
Other$11,910 (15.2%)
Travel$8,429 (10.7%)
Education$1,182 (1.5%)
Research$1,094 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $37,851 | 13 | 48.2% |
| Food and Beverage | $18,046 | 781 | 23.0% |
| Travel and Lodging | $8,429 | 38 | 10.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,995 | 4 | 8.9% |
| Honoraria | $4,915 | 2 | 6.3% |
| Education | $1,182 | 20 | 1.5% |
| Unspecified | $1,094 | 1 | 1.4% |
Payments by Type
General
$77,418
858 transactions
Research
$1,094
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $9,962 | 69 | $0 (2024) |
| EMD Serono, Inc. | $9,536 | 7 | $0 (2024) |
| GENZYME CORPORATION | $7,567 | 20 | $0 (2024) |
| Exelixis Inc. | $7,299 | 38 | $0 (2024) |
| ABBVIE INC. | $5,812 | 23 | $0 (2024) |
| Incyte Corporation | $4,842 | 25 | $0 (2024) |
| Novocure Inc. | $4,688 | 18 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $3,473 | 82 | $0 (2024) |
| GlaxoSmithKline, LLC. | $2,899 | 18 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $2,471 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17,391 | 139 | EMD Serono, Inc. ($9,165) |
| 2023 | $16,900 | 175 | Incyte Corporation ($3,906) |
| 2022 | $6,942 | 124 | Exelixis Inc. ($4,396) |
| 2021 | $3,986 | 61 | GlaxoSmithKline, LLC. ($2,628) |
| 2020 | $122.01 | 1 | E.R. Squibb & Sons, L.L.C. ($122.01) |
| 2019 | $13,452 | 25 | GENZYME CORPORATION ($7,296) |
| 2018 | $8,262 | 171 | AbbVie, Inc. ($5,571) |
| 2017 | $11,459 | 163 | Genentech USA, Inc. ($9,200) |
All Payment Transactions
859 individual payment records from CMS Open Payments — Page 1 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $14.62 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $16.14 | General |
| Category: Oncology | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $22.32 | General |
| Category: Oncology | ||||||
| 12/11/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $31.90 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $21.21 | General |
| Category: Rare Disease | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TALVEY, TECVAYLI | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: Oncology | ||||||
| 11/27/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $22.88 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $22.42 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Exelixis Inc. | CABOMETYX (Drug) | Honoraria | Cash or cash equivalent | $1,715.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $30.94 | General |
| Category: Oncology | ||||||
| 11/14/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.48 | General |
| 11/12/2024 | Azurity Pharmaceuticals, Inc. | VIVIMUSTA (Drug) | Food and Beverage | In-kind items and services | $23.23 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $27.01 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Genentech USA, Inc. | Itovebi (Biological), Phesgo, Tecentriq Hybreza | Food and Beverage | In-kind items and services | $28.19 | General |
| Category: BioOncology | ||||||
| 10/30/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $17.75 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.52 | General |
| 10/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | Cash or cash equivalent | $355.10 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $354.53 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $68.50 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | Cash or cash equivalent | $55.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $51.38 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $28.54 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Open-Label, Dose-Escalation, Phase 1-2 Study of the Oral Formulation of MLN9708 Administered Twice-weekly in Combination with Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment | Takeda Pharmaceuticals U.S.A., Inc. | $1,094 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 37 | 2,538 | 28,846 | $1.7M | $700,048 |
| 2022 | 49 | 3,430 | 101,795 | $2.7M | $915,512 |
| 2021 | 53 | 3,796 | 103,193 | $2.5M | $936,846 |
| 2020 | 8 | 708 | 1,516 | $223,638 | $75,636 |
Total Patients
10,472
Total Services
235,350
Medicare Billing
$2.6M
Procedure Codes
149
All Medicare Procedures & Services
149 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 21 | 7,441 | $282,758 | $134,580 | 47.6% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 16 | 3,638 | $309,230 | $129,956 | 42.0% |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | Office | 2023 | 16 | 5,016 | $300,960 | $129,231 | 42.9% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 47 | 5,400 | $270,000 | $89,865 | 33.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 338 | 925 | $203,500 | $84,105 | 41.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 78 | 158 | $47,400 | $20,911 | 44.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 49 | 202 | $54,136 | $19,342 | 35.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 77 | 77 | $31,570 | $12,357 | 39.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 456 | 1,458 | $29,160 | $10,960 | 37.6% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 12 | 24 | $33,360 | $9,788 | 29.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 453 | 1,258 | $19,464 | $9,773 | 50.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 90 | 172 | $23,736 | $7,610 | 32.1% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 92 | 128 | $23,168 | $6,036 | 26.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 33 | 77 | $11,165 | $4,629 | 41.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 25 | $10,000 | $3,296 | 33.0% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 47 | 136 | $13,600 | $3,239 | 23.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 88 | 309 | $11,742 | $3,189 | 27.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 16 | 65 | $8,450 | $3,087 | 36.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 155 | 273 | $6,552 | $2,765 | 42.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $6,400 | $2,263 | 35.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 51 | 198 | $7,920 | $2,217 | 28.0% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 17 | 27 | $5,400 | $1,762 | 32.6% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 11 | 11 | $3,817 | $1,441 | 37.8% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 27 | 92 | $3,864 | $1,379 | 35.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 17 | 63 | $3,780 | $1,320 | 34.9% |
About Dr. Nasfat Shehadeh, MD
Dr. Nasfat Shehadeh, MD is a Hematology & Oncology healthcare provider based in Charlotte, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1538241369.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nasfat Shehadeh, MD has received a total of $78,512 in payments from pharmaceutical and medical device companies, with $17,391 received in 2024. These payments were reported across 859 transactions from 81 companies. The most common payment nature is "Consulting Fee" ($37,851).
As a Medicare-enrolled provider, Shehadeh has provided services to 10,472 Medicare beneficiaries, totaling 235,350 services with total Medicare billing of $2.6M. Data is available for 4 years (2020–2023), covering 149 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Charlotte, NC
- Active Since 10/20/2006
- Last Updated 01/27/2026
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1538241369
Products in Payments
- CD38 (Drug) $7,164
- Herceptin (Biological) $4,600
- Cabometyx (Drug) $4,540
- Oncology (Device) $4,508
- TECENTRIQ (Biological) $4,415
- Venclexta (Drug) $3,361
- CABOMETYX (Drug) $2,759
- BLENREP (Biological) $2,709
- VONJO (Drug) $2,423
- Epkinly (Drug) $2,282
- Onivyde (Drug) $2,249
- PIQRAY (Drug) $2,025
- IBRANCE (Drug) $1,517
- IMFINZI (Biological) $1,441
- Revlimid (Drug) $1,147
- KEYTRUDA (Biological) $669.34
- OPDIVO (Biological) $631.79
- IMBRUVICA (Drug) $432.86
- Lenvima (Drug) $365.48
- XARELTO (Drug) $314.63
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Charlotte
Dr. Alan Zausner Skarbnik, Md, MD
Hematology & Oncology — Payments: $1.3M
Hematology & Oncology $1.3M
Shebli Atrash, Md, MD
Hematology & Oncology — Payments: $718,073
Hematology & Oncology $718,073
Ruben Mesa, Md, MD
Hematology & Oncology — Payments: $474,884
Hematology & Oncology $474,884
Justin Favaro, Md, MD
Hematology & Oncology — Payments: $35,791
Hematology & Oncology $35,791
Bei Hu, Md, MD
Hematology & Oncology — Payments: $16,154
Hematology & Oncology $16,154
Brittany Ragon, Md, MD
Hematology & Oncology — Payments: $13,167
Hematology & Oncology $13,167